Abstract: The invention provides a free radical-induced intracellular DNA damage reducing reagent, including: an effective amount of a Gracilaria sp. extract, serving as an active ingredient, wherein the free radical-induced intracellular DNA damage reducing reagent is capable of reducing free radical-induced intracellular DNA damage. The invention also provides a free radical-induced intracellular DNA damage reducing medicament or health food and a free radical-induced intracellular DNA damage reducing skin care product or cosmetic.
Type:
Application
Filed:
February 23, 2011
Publication date:
July 26, 2012
Applicants:
KAOHSIUNG MEDICAL UNIVERSITY, NATIONAL KAOHSIUNG MARINE UNIVERSITY
Abstract: The theophylline derivative disclosed in the present invention is characterized by having the pharmaceutical functions of osteoporosis. The theophylline derivative protects against bone resorption and inflammatory mediator infiltration.
Abstract: Disclosed are a method for preparing an n-hexane extract of the fruiting body of Antrodia cinnamomea (AC), wherein the fruiting body of AC is sequentially extracted with the ethanol solution and the n-hexane solution to obtain the n-hexane extract containing at least one benzenoid compound. The amounts of 4,7-dimethoxy-5-(3-methylbut-3-en-1-ynyl)-6-methyl-1,3-benzodioxole, 4,7-dimethoxy-5-methyl-1,3-benzodioxole, antrocamphine A and the combination thereof in the at least one benzenoid compound are determined using chromatography, NMR and HPLC. In addition, the present invention is applicable on detecting the amounts of benzenoid compounds in the AC healthcare food/drug or the fruiting body of AC, and thus owns the industrial values.
Abstract: A method for conjugating a nucleic acid with a molecule is provided. The method includes steps of (a) reacting the nucleic acid having a 5?-monophosphate with an activating agent in a first buffer to form a solution; (b) mixing an alcohol with the solution formed in the step (a) to obtain an intermediate; and (c) dissolving the intermediate in a second buffer containing an ethylenediaminetetraacetic acid (EDTA) and adding a nucleophile thereinto to react the intermediate with the nucleophile.
Abstract: Disclosed are the nanoparticle and the method for the same, and the preparing method includes steps of mixing polyethylenimine (PEI) with the poly(acrylic acid)-bound iron oxide (PAAIO) to form a PEI-PAAIO polyelectrolyte complex (PEC) and mixing the PEI-PAAIO PEC with genetic material such as plasmid DNA to form the PEI-PAAIO/pDNA magnetic nanoparticle. The PEI-PAAIO/pDNA magnetoplex is highly water dispersible and suitable for long term storage, shows superparamagnetism, low cytotoxicity, high stability and nice transfection efficiency, and thus the PEI-PAAIO PEC can replace PEI as a non-viral gene vector.
Abstract: A preparation method for an ethanol extract of the fruiting body of Antrodia camphorata (EEAC) is provided. The preparation method includes steps of: (a) providing the fruiting body of A. camphorata (AC); (b) extracting the fruiting bodies with a first ethanol solution; and (c) obtaining EEAC. EEAC further can be sequentially extracted or fractioned by n-hexane, ethyl acetate and ethanol, and an n-hexane fraction (FC), an ethyl acetate fraction (FA) and an ethanol fraction (FB) respectively are generated. The growth inhibition and apoptosis induction of leukemia cell line HL 60 are effectively mediated by FA product, in which zhankuic acid A is the bioactive marker. The amount of triterpenoid in the fruiting body of AC can be determined by NMR and HPLC analysis.
Abstract: A series of amine salts including a structure of formula (I) and formula (III) have provided. In formula I or formula (III), R1, Ra and RX are as defined in the specification. The amine complex salts disclosed in the present invention are characterized in a pro-drug active form and various pharmaceutical function.
Abstract: The invention provides a method for determining a risk for kidney stones to develop in a subject, including: obtaining a biosample of the subject; detecting the presence of the single-nucleotide polymorphism rs12313273 (C/T) at position 30881 of the ORAI1 gene (SEQ ID No.: 1) in the biosample; and determining a risk for kidney stones to develop in the subject, wherein if the presence of a C allele of the single-nucleotide polymorphism rs12313273 (C/T) is detected, it indicates that the subject has an increased risk for kidney stones to develop.
Abstract: The invention relates to a pharmaceutical composition for treating serotonergic neurotransmission related disease or condition, including an effective amount of a chlorophenylpiperazine derived compound of Formula (I), or the pharmaceutically acceptable salt thereof. The pharmaceutical composition is safe and does not have side effect on lethargy.
Abstract: A pharmaceutical composition for improving a cardiac function is provided. The pharmaceutical composition comprises an effective amount of an active component being one of a KMUP-3 compound and a salt thereof.
Abstract: A method for gender identification of eagles includes: providing a DNA of an eagle; performing a probe-based real-time PCR using the DNA as a template, a universal primer pair P2/P8 as a primer pair and a first probe and a second probe as probes, wherein the 5? ends of the first probe and the second probe are labeled with a first fluorescent dye and a second fluorescent dye, respectively, and the first probe is a sequence with about 15-38 nucleotides in length of SEQ ID No. 1 and the second probe is a sequence with about 15-44 nucleotides in length of SEQ ID No. 2; and analyzing a result of the PCR, wherein if the result is positive for both the first and the second fluorescent dye, the eagle is a female, and if the result is positive for only the first fluorescent dye, the eagle is a male.
Type:
Grant
Filed:
September 11, 2008
Date of Patent:
April 17, 2012
Assignee:
Kaohsiung Medical University
Inventors:
Hsueh-Wei Chang, Chien-Chung Cheng, De-Leung Gu, San-Hua Su
Abstract: Disclosed herein is a method for preparing a coumarin compound of formula (F), in which R1, R2, and R3 are independently H, C1˜C7 alkoxy, C1˜C7 alkyl, phenoxy, benzyloxy, or a halogen atom; R4 is an alkyl group; and Ar is an optionally substituted aryl group, the method including: treating a chromene compound having the following formula (E) with an acid in the presence of water. A chromene compound of formula (E) and a method for preparing the chromene compound of formula (E) are also disclosed.
Abstract: An isoxazole derivative is provided. The isoxazole derivative has following formula: wherein R1, R2, R3, R4 and R5, independently, include hydrogen, hydroxy or C1-C12 alkoxy optionally substituted with oxirane, thiirane, aziridine, amino, cycloamino, aminohydroxy or cycloaminohydroxy. The invention also provides a pharmaceutical composition for treatment of osteoporosis and cancer including an isoxazole derivative or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
Abstract: The present invention relates to a bisphosphonates and synthetic polymeric carriers to form a sustained release system. The present invention also provides a method for preparing a sustained release system, comprising activation of the synthetic polymeric carriers and the cross linking reaction. The present invention further provides methods for enhancing stem cell differentiation into osteogenic lineage and chondrogenic lineage, which comprise culturing a population of stem cells in specific micro-environments.
Abstract: The invention provides a method for determining a risk, for a subject, of suffering from atopic dermatitis, including: obtaining a biosample of the subject; detecting the presence of the single-nucleotide polymorphism rs12313273 (C/T) at position 30881 of the ORAI1 gene (SEQ ID No.: 1) in the biosample; and determining the risk, for the subject, of suffering from atopic dermatitis, wherein the presence of a C allele or genotype CC of the single-nucleotide polymorphism rs12313273 (C/T) indicates that the subject is at increased risk for suffering from atopic dermatitis.
Abstract: In this invention, anti-PEG antibodies or anti-methoxyl-PEG (anti-CH3O-PEG) antibodies were expressed on cell surface which can collocate with a biotinylated anti-PEG antibody (AGP4-Biotin) or biotinylated PEG (PEG-Biotin) to develop a cell-based sandwich ELISA or a cell-based competition ELISA, respectively. Both of these two methods could sensitively quantify free PEG and PEG-modified macromolecules (proteins, nanoparticles and liposomes) as sensitive as nano-gram level.
Type:
Application
Filed:
February 22, 2011
Publication date:
January 19, 2012
Applicant:
KAOHSIUNG MEDICAL UNIVERSITY
Inventors:
Tian-Lu Cheng, Steven R. Roffler, Kuo-Hsiang Chuang, Ssu-Jung Lu
Abstract: The present disclosure uses different kinds of surface treatment processes on titanium-made dental implants. The growth and attachment conditions of bone cells (MC3T3-E), fibroblasts(NIH 3T3) and epidermal cells (XB-2) on the metal surface of titanium slices with different surface treatments are observed. Tetra-calcium phosphate is used to perform secondary sand-blasting process to clean up the metal surface and provide calcium ions for osteoblastoma physiology. Thus, by adjusting the cells adhesive and proliferative abilities, the success rate of the clinical applications in dental implant is improved.
Type:
Application
Filed:
September 1, 2010
Publication date:
December 29, 2011
Applicant:
KAOHSIUNG MEDICAL UNIVERSITY
Inventors:
Wen-Cheng Chen, Chun-Cheng Hung, Chia-Ling Ko
Abstract: A novel nanoparticle and use thereof were provided in the present invention. In particular, the nanoparticle is used for delivering therapeutic component, such as oligonucleotide and hydrophobic drug.
Abstract: A controlled release system and manufacturing method is provided. The method comprises providing a first aqueous solution containing a hydrophilic drug and an alkaline agent, providing an organic solution containing a hydrophobic molecule, providing a second aqueous solution containing a hydrophilic surfactant, mixing the first hydrophilic solution with the organic solution to form a first emulsion, and mixing the first emulsion with a second aqueous solution to form a second emulsion containing delayed-release microsphere.
Abstract: The present invention provides a method for producing a controlled release microsphere with mean average size greater than 50 ?m, comprising preparing a water-in-oil (w/o) emulsion comprising an inner aqueous layer containing a pharmaceutically effective amount of a biologically active polypeptide with activity similar to parathyroid hormone, and an oil layer containing a polymer substance of poly (lactic-co-glycolic acid) (PLGA), then adding the w/o emulsion into aqueous polyvinyl alcohol (PVA) solution to form a water-in-oil-in-water (w/o/w) double emulsion and then desorbing the solvent in the oil layer. The present invention also provides a controlled release microsphere prepared by the method and use thereof.